Selected studies of Novel agents as secondary therapy in CGVHD

Study	Novel Therapy	Sample size	Response	Survival(follow up)
Lopez et al.(15)	MMF	24	75%	85% (2 years)
Baudard et al.(5)	MMF	15	69%	80% (19.5 months)
Mookerjee et al.(16)	MMF	26	46%	-
Ratanatharathorn et al.(17)	Rituximab	8	50%	100% (27–99 months)
Cutler et al.(6)	Rituximab	21	70%	-
Couriel et al.(7)	Sirolimus	35	63%	41% (2 years)
Jurado et al.(18)	Sirolimus	47	81%	57% (3 years)
Flowers et al (randomized trial of ECP vs. no ECP)(9)	ECP	95	Improvement in skin score 14.5% in ECP arm vs 10.4% in non ECP arm (NS)	98% in ECP arm, 94% in non ECP arm (12 weeks)
Couriel et al.(8)	ECP	71	61%	53% (1 year)
Gilman et al.(12)	Hydroxychloroquine	40	53%	75% in responders, 40% in nonresponders(30 months)
Akpek et al.(10)	Pulsed steroids	61	75%	81% (2 years)
Jacobsohn et al.(11)	Pentostatin	58	55%	70% (2 years)
Browne et al.(19)	Thalidomide	37	38%	41% (2years)
Parker et al.(14)	Thalidomide	80	20%	53% (2.7 years)